Drug/Small Molecule:
methoxamine

PharmGKB contains no dosing guidelines for this drug/small molecule. To report known genotype-based dosing guidelines, or if you are interested in developing guidelines, click here.

PharmGKB contains no drug labels with pharmacogenomic information for this drug/small molecule. To report a drug label with PGx, click here.

Disclaimer: The PharmGKB's clinical annotations reflect expert consensus based on clinical evidence and peer-reviewed literature available at the time they are written and are intended only to assist clinicians in decision-making and to identify questions for further research. New evidence may have emerged since the time an annotation was submitted to the PharmGKB. The annotations are limited in scope and are not applicable to interventions or diseases that are not specifically identified.

The annotations do not account for individual variations among patients, and cannot be considered inclusive of all proper methods of care or exclusive of other treatments. It remains the responsibility of the health-care provider to determine the best course of treatment for a patient. Adherence to any guideline is voluntary, with the ultimate determination regarding its application to be made solely by the clinician and the patient. PharmGKB assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of the PharmGKB clinical annotations, or for any errors or omissions.

? = Mouse-over for quick help

This is a non-comprehensive list of genetic tests with pharmacogenetics relevance, typically submitted by the manufacturer and manually curated by PharmGKB. The information listed is provided for educational purposes only and does not constitute an endorsement of any listed test or manufacturer.

A more complete listing of genetic tests is found at the Genetic Testing Registry (GTR).

PGx Test Variants Assayed Gene?
2D structure from PubChem
provided by PubChem

Overview

Generic Names
Trade Names
  • Methoxamedrine
  • Methoxamin
  • Methoxaminum [INN-Latin]
  • Metossamina [DCIT]
  • Metoxamina [INN-Spanish]
  • Pseudomethoxamine
  • Vasoxine
  • Vasoxyl
Brand Mixture Names

PharmGKB Accession Id:
PA450431

Description

An alpha-adrenergic agonist that causes prolonged peripheral vasoconstriction. It has little if any direct effect on the central nervous system.

Source: Drug Bank

Indication

Indicated for the treatment and management of hypotension.

Source: Drug Bank

Other Vocabularies

Information pulled from DrugBank has not been reviewed by PharmGKB.

Pharmacology, Interactions, and Contraindications

Mechanism of Action

Methoxamine acts through peripheral vasoconstriction by acting as a pure alpha-1 adrenergic receptor agonist, consequently increasing systemic blood pressure (both systolic and diastolic).

Source: Drug Bank

Pharmacology

Methoxamine is a potent sympathomimetic amine that increases both systolic and diastolic blood pressure. Methoxamine is indicated for prevention and treatment of the acute hypotensive state occurring with spinal anesthesia. It is also indicated as adjunctive treatment of hypotension due to hemorrhage, reactions to medications, surgical complications, and shock associated with brain damage due to trauma or tumor. Methoxamine acts on both alpha1-adrenergic receptors but appears to have no effect on beta-adrenergic receptors. It acts by increasing the force of the heart's pumping action as well as constricting peripheral blood vessels.

Source: Drug Bank

Absorption, Distribution, Metabolism, Elimination & Toxicity

Protein Binding

Low

Source: Drug Bank

Chemical Properties

Chemical Formula

C11H17NO3

Source: Drug Bank

Isomeric SMILES

C[C@H]([C@@H](C1=C(C=CC(=C1)OC)OC)O)N

Source: Drug Bank

COC1=CC(C(O)C(C)N)=C(OC)C=C1

Source: Drug Bank

Canonical SMILES

COC1=CC(C(O)C(C)N)=C(OC)C=C1

Source: Drug Bank

Average Molecular Weight

211.2576

Source: Drug Bank

Monoisotopic Molecular Weight

211.120843415

Source: Drug Bank

PharmGKB Curated Pathways

Pathways created internally by PharmGKB based primarily on literature evidence.

  1. Sympathetic Nerve Pathway (Neuroeffector Junction)
    Simplified diagram of a sympathetic neuroeffector junction displaying genes which may be involved.

External Pathways

Links to non-PharmGKB pathways.

PharmGKB contains no links to external pathways for this drug. To report a pathway, click here.

Genes that are associated with this drug in PharmGKB's database based on (1) variant annotations, (2) literature review, (3) pathways or (4) information automatically retrieved from DrugBank, depending on the "evidence" and "source" listed below.

Curated Information ?

EvidenceGene
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available PW
ADRA1A
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available PW
ADRA1B
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available PW
ADRA1D

Drug Targets

Gene Description
ADRA1A (source: Drug Bank)
ADRA1B (source: Drug Bank)

Drug Interactions

Drug Description
methoxamine The tricyclic increases the sympathomimetic effect (source: Drug Bank)
methoxamine The tricyclic antidepressant, amitriptyline, increases the sympathomimetic effect of methoxamine. (source: Drug Bank)
methoxamine The tricyclic increases the sympathomimetic effect (source: Drug Bank)
methoxamine The tricyclic antidepressant, amoxapine, increases the sympathomimetic effect of methoxamine. (source: Drug Bank)
methoxamine The tricyclic increases the sympathomimetic effect (source: Drug Bank)
methoxamine The tricyclic antidepressant, clomipramine, increases the sympathomimetic effect of methoxamine. (source: Drug Bank)
methoxamine The tricyclic increases the sympathomimetic effect (source: Drug Bank)
methoxamine The tricyclic antidepressant, desipramine, increases the sympathomimetic effect of methoxamine. (source: Drug Bank)
methoxamine The tricyclic increases the sympathomimetic effect (source: Drug Bank)
methoxamine The tricyclic antidepressant, doxepin, increases the sympathomimetic effect of methoxamine. (source: Drug Bank)
methoxamine The agent decreases the effect of guanethidine (source: Drug Bank)
methoxamine Methoxamine may decrease the effect of guanethidine. (source: Drug Bank)
methoxamine The tricyclic increases the sympathomimetic effect (source: Drug Bank)
methoxamine The tricyclic antidepressant, imipramine, increases the sympathomimetic effect of methoxamine. (source: Drug Bank)
methoxamine Increased arterial pressure (source: Drug Bank)
methoxamine Increased arterial pressure (source: Drug Bank)
methoxamine Increased arterial pressure (source: Drug Bank)
methoxamine Increased arterial pressure (source: Drug Bank)
methoxamine Possible increase of arterial pressure (source: Drug Bank)
methoxamine Possible increase of arterial pressure (source: Drug Bank)
methoxamine Increased arterial pressure (source: Drug Bank)
methoxamine Moclobemide increases the sympathomimetic effect (source: Drug Bank)
methoxamine Moclobemide increases the sympathomimetic effect of methoxamine. (source: Drug Bank)
methoxamine The tricyclic increases the sympathomimetic effect (source: Drug Bank)
methoxamine The tricyclic antidepressant, nortriptyline, increases the sympathomimetic effect of methoxamine. (source: Drug Bank)
methoxamine Increased arterial pressure (source: Drug Bank)
methoxamine Increased arterial pressure (source: Drug Bank)
methoxamine Increased arterial pressure (source: Drug Bank)
methoxamine Increased arterial pressure (source: Drug Bank)
methoxamine Increased arterial pressure (source: Drug Bank)
methoxamine The MAO inhibitor, Tranylcypromine, may increase the vasopressor effect of the alpha1-agonist, Methoxamine. Concomitant therapy should be avoided. (source: Drug Bank)
methoxamine Trimipramine may increase the vasopressor effect of the alpha1-agonist, Methoxamine. Avoid combination if possible. Monitor sympathetic response to therapy if used concomitantly. (source: Drug Bank)
No related diseases are available

LinkOuts

Web Resource:
Wikipedia
DrugBank:
DB00723
KEGG Compound:
C07513
PubChem Compound:
6082
PubChem Substance:
46506264
9716
IUPHAR Ligand:
483
Drugs Product Database (DPD):
4480
BindingDB:
50026777
ChemSpider:
5857
Therapeutic Targets Database:
DAP000796

Clinical Trials

These are trials that mention methoxamine and are related to either pharmacogenetics or pharmacogenomics.

Common Searches

Search PubMed
Search Medline Plus
Search PubChem
Search CTD

Sources for PharmGKB drug information: DrugBank, Open Eye Scientific Software.